Radiofrequency ablation for intrahepatic hepatocellular carcinoma and percutaneous ethanol injection for portal vein tumor thrombus: safety and feasibility.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: PVTT, which might reduce the tumor burden and create conditions for further adjuvant therapy
I · Intervention 중재 / 시술
RFA for intrahepatic tumor combined with PEI for PVTT were enrolled
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Major complication of liver abscess was observed in only 1 (4%) patient. [CONCLUSIONS] RFA combined with PEI is a feasible treatment for HCC patients with PVTT, which might reduce the tumor burden and create conditions for further adjuvant therapy.
[AIMS] To assess the viability and safety of radiofrequency ablation (RFA) for intrahepatic tumors in hepatocellular carcinoma (HCC) treatment, as well as percutaneous ethanol injection (PEI) for port
- p-value p=0.026
APA
Lin K, Wang Y, et al. (2026). Radiofrequency ablation for intrahepatic hepatocellular carcinoma and percutaneous ethanol injection for portal vein tumor thrombus: safety and feasibility.. Medical ultrasonography, 28(1), 7-15. https://doi.org/10.11152/mu-4537
MLA
Lin K, et al.. "Radiofrequency ablation for intrahepatic hepatocellular carcinoma and percutaneous ethanol injection for portal vein tumor thrombus: safety and feasibility.." Medical ultrasonography, vol. 28, no. 1, 2026, pp. 7-15.
PMID
40789011 ↗
DOI
10.11152/mu-4537
Abstract 한글 요약
[AIMS] To assess the viability and safety of radiofrequency ablation (RFA) for intrahepatic tumors in hepatocellular carcinoma (HCC) treatment, as well as percutaneous ethanol injection (PEI) for portal vein tumor thrombus (PVTT).
[MATERIALS AND METHODS] From January 2010 to December 2020, a total of 25 HCC patients who underwent RFA for intrahepatic tumor combined with PEI for PVTT were enrolled. Treatment response (assessed using modified Response Evaluation Criteria in Solid Tumors [mRECIST] based on contrast-enhanced computed tomography [CECT] or contrast-enhanced ultrasound [CEUS]), overall survival (OS), progression-free survival (PFS), and safety profile were evaluated. Univariate and multivariate analyses were performed to identify the prognostic factors in predicting the OS and PFS.
[RESULTS] The overall response rate was 88%, including 12 (48%) patients achieving complete response (CR) and 10 (40%) patients achieving partial response (PR). Progressive disease (PD) was observed in 3 (12%) patients. The 1-, 3-, 6-, and 12- month PFS rates were 96%, 56%, 20%, and 4%, respectively. The OS rates at 6, 12, 24, 36, and 48 months were 96%, 52%, 28%, 8%, and 4%, respectively. The overall response was the only risk factor for the PFS in the univariate analysis (p=0.026), but not in the multivariate analysis (p=0.288). There was no independent prognostic factor of OS. No ablation-related mortality was observed. Major complication of liver abscess was observed in only 1 (4%) patient.
[CONCLUSIONS] RFA combined with PEI is a feasible treatment for HCC patients with PVTT, which might reduce the tumor burden and create conditions for further adjuvant therapy.
[MATERIALS AND METHODS] From January 2010 to December 2020, a total of 25 HCC patients who underwent RFA for intrahepatic tumor combined with PEI for PVTT were enrolled. Treatment response (assessed using modified Response Evaluation Criteria in Solid Tumors [mRECIST] based on contrast-enhanced computed tomography [CECT] or contrast-enhanced ultrasound [CEUS]), overall survival (OS), progression-free survival (PFS), and safety profile were evaluated. Univariate and multivariate analyses were performed to identify the prognostic factors in predicting the OS and PFS.
[RESULTS] The overall response rate was 88%, including 12 (48%) patients achieving complete response (CR) and 10 (40%) patients achieving partial response (PR). Progressive disease (PD) was observed in 3 (12%) patients. The 1-, 3-, 6-, and 12- month PFS rates were 96%, 56%, 20%, and 4%, respectively. The OS rates at 6, 12, 24, 36, and 48 months were 96%, 52%, 28%, 8%, and 4%, respectively. The overall response was the only risk factor for the PFS in the univariate analysis (p=0.026), but not in the multivariate analysis (p=0.288). There was no independent prognostic factor of OS. No ablation-related mortality was observed. Major complication of liver abscess was observed in only 1 (4%) patient.
[CONCLUSIONS] RFA combined with PEI is a feasible treatment for HCC patients with PVTT, which might reduce the tumor burden and create conditions for further adjuvant therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Elevation of Liver Elastic Value Following Radiofrequency Ablation Reflected Neutrophils Mediated Abscopal Effect in Liver Cancer.
- Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
- Bibliometric analysis of programmed death ligand-1 positron emission tomography probe research: development, landscape, and technological evolution.
- Long non-coding RNA PVT1 mediates bile acid-induced gastric intestinal metaplasia via a miR-34b-5p/HNF4α positive feedback loop.
- IGF2BP3 boosts lactate generation to accelerate gastric cancer immune evasion.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.